University of Florida researchers, in a collaborative effort across the country, analyzed medical outcomes in 1,815 patients who had undergone simple, precise genetic testing at the time of their cardiac procedure for a coronary artery stent. In efforts to better prescribe individual patients, the genetic test offered insight into those patients who were unable to effectively metabolize the anti-clotting drug clopidogrel, a drug administered following such a procedure. Outcomes of the study spoke volumes:
"About 60 percent of patients with the genetic deficiency were given a different, more effective medication. Using the genetic data to guide changes in therapy reduced the percentage of deaths, heart attacks or strokes by nearly half compared with those who continued taking clopidogrel, the researchers found. Among those who had the genetic deficiency and continued taking clopidogrel, 8 percent of patients experienced one of those complications."
Read more below on the successful clinical implementation of pharmacogenomics for individual patients.